Revefenacin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Revefenacin
Revefenacin.svg
Clinical data
Trade namesYupelri
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC35H43N5O4
Molar mass597.760 g·mol−1
3D model (JSmol)

Revefenacin (trade name Yupelri) is a pharmaceutical drug for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[2]

Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.[3]

References[edit]

  1. ^ "Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. November 9, 2018.
  2. ^ Heo, Young-A (2018). "Revefenacin: First Global Approval". Drugs. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.
  3. ^ Donohue, James; Kerwin, Edward; Barnes, Chris; Moran, Edmund; Haumann, Brett; Pendyala, Srikanth; Crater, Glenn (2018). "Efficacy of Revefenacin, A Long-Acting Muscarinic Antagonist for Nebulized Therapy, in Copd Patients with Markers of More Severe Disease". Chest. 154 (4): 736A–737A. doi:10.1016/j.chest.2018.08.665.